Overview

A Trial Of Neoadjuvant Chemotherapy or Radiochemotherapy With Or Without SHR-1210 In Patients With Resectable ESCC.

Status:
Not yet recruiting

Trial end date:
2026-03-06

Target enrollment:

Participant gender:

Summary

The purpose of this study is to explore the effectiveness and safety of neoadjuvant immune combined chemotherapy or radiochemotherapy compared with traditional neoadjuvant radiochemotherapy in patients with locally advanced Esophageal Squamous Cell Carcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

Zhigang Li

Collaborator:

Jiangsu HengRui Medicine Co., Ltd.

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Paclitaxel